Celiac Disease
Stories
-
Interlude Biopharma registers Phase 3 trial of larazotide acetate in celiac disease
The study plans to enroll 414 participants and is expected to start in February 2027, with primary completion projected for August 2028. It is a randomized, double-blinded, placebo-controlled trial testing two doses of larazotide acetate to learn if it can help prevent signs and symptoms of celiac disease in well-controlled patients aged 12 and up.